Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + quavonlimab
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Pembrolizumab + quavonlimab is a fixed-dose combination of two monoclonal antibodies developed as an immunotherapy for cancer. Pembrolizumab is a humanized monoclonal antibody that targets and inhibits the programmed cell death protein 1 receptor (PD-1) on T cells, thereby blocking an inhibitory pathway and enhancing T-cell mediated immune responses against tumor cells. Quavonlimab is a monoclonal antibody that targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), another immune checkpoint, further promoting anti-tumor immunity by stimulating T-cell activation. The combination aims to provide synergistic effects by dual checkpoint inhibition, and it is being investigated in multiple advanced solid tumors including renal cell carcinoma, hepatocellular carcinoma, melanoma, colorectal cancer, small cell lung cancer, non-small cell lung cancer, and other solid tumors[1][3][4][7].
- Other names
- coformulation pembrolizumab/quavonlimabPembrolizumab/quavonlimab - Merck Sharp & Dohme
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + quavonlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + quavonlimab.